<DOC>
	<DOCNO>NCT02315638</DOCNO>
	<brief_summary>This long-term safety follow-up protocol subject receive TT-034 B2801001 protocol consist monitor least 4.5 year .</brief_summary>
	<brief_title>Long-Term Follow-Up Safety Monitoring Patients Dosed First-in-Man Phase I/II Study TT-034 .</brief_title>
	<detailed_description>The main purpose follow-up study detect event suggestive delayed adverse effect study drug review clinical history discussion subject identify/elicit significant medical event , include limited hematologic , malignant , autoimmune , neurologic , hepatic event .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Prior enrollment Study B2801001 dose TT034 An informed consent form study sign date subject legally acceptable representative There specific exclusion criterion followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adeno-associated viral vector</keyword>
	<keyword>Adeno-associated virus</keyword>
	<keyword>AAV</keyword>
	<keyword>AAV8</keyword>
	<keyword>ddRNAi</keyword>
	<keyword>shRNA</keyword>
	<keyword>RNAi</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>CHC</keyword>
	<keyword>Genotype 1</keyword>
</DOC>